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ABSTRACT
Quercetin, a bioactive flavonoid with anti-inflammatory, immunosuppressive and 
protective properties, is a possible agent for Rheumatoid Arthritis (RA). Collagen-
induced arthritis (CIA) is the most common animal model to study the pathogenesis of 
RA. This study analysed the therapeutic role of quercetin in collagen-induced arthritis 
in C57BL/6 mice. Animals were allocated into five groups: negative control, positive 
control (arthritis), arthritis+methotrexate, arthritis+quercetin and 
arthritis+methotrexate+quercetin. Weight, oedema, joint damage and cytokines 
production were assessed to determine the therapeutic effect of quercetin. This study 
demonstrates for the first time that quercetin has anti-inflammatory and protective roles 
in vivo in CIA. We also report that quercetin and methotrexate administered 
concurrently show no more protection than a single agent. Quercetin as a 
monotherapeutic agent showed the lowest degree of joint inflammation and the highest 
protection. Less severe disease in animals treated with quercetin was associated with 
decreased levels of TNF-, IL-1, IL-17 and MCP-1. In conclusion, this study supports 
the argument that quercetin produces better results with no known toxicity than 
methotrexate in safeguarding joints from arthritic inflammation in mice. Quercetin 
could be an alternative treatment for RA because it modulates the main pathogenic 
pathways of RA. 
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1. Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory and degenerative joint disease 
affecting all ages, sexes and races [1, 2]. RA is characterized by swelling, pain and 
stiffness in joints but it can also damage the heart, eyes, lungs, kidneys, and skin [3-7]. 
Patients with RA suffer progressive disability and increased risk of death [8]. Genetic, 
hormonal and environmental factors have been related to RA [9-12]. 
Advances to develop new treatments for RA have relied on animal models. The 
collagen-induced arthritis (CIA), model of RA, closely replicates the pathogenesis of 
the disease. Currently, therapeutic products for RA include: 1) Conventional synthetic 
disease-modifying antirheumatic drugs (DMARDs) such as methotrexate (Mtx), 
sulfasalazine, leflunomide and hydroxychloroquine; 2) Biological DMARDs such as 
TNF inhibitors, anti-B cell, anti-T cell and anti-IL6 R; and 3) Targeted synthetic 
DMARDs such as Janus kinase inhibitors [13]. Of all these medications, methotrexate 
continues to be the most widely used treatment for RA because of its 
immunosuppressive and anti-inflammatory effects as well as low cost. However, 
methotrexate is not an ideal therapeutic agent due to its toxicity. Methotrexate has 
adverse effects on the neuronal, gastrointestinal, reproductive, respiratory, urinary, 
integumentary, cardiovascular and immune systems [14]. Therefore, there is a need to 
develop better affordable therapeutic agents for RA. 
Quercetin (Que) is a natural flavonoid found in vegetables, fruits, grains and nuts [15, 
16]. This flavonoid does not cause toxicity or have secondary effects [17-21]. Plants 
containing quercetin such as Bridelia ferruginea, Betula pendula and Poligonum 
hydropiper L. have been used in traditional medicine for arthritic pain [22-24]. Que has 
been described to have several effects including antioxidant, anti-proliferative, anti-
inflammatory, antihistamine, antiviral, anti-carcinogenic, psychostimulatory, 
immunosuppressive and protective properties. [16]. Studies in vitro, ex vivo and in vivo 
indicate that quercetin disturbs different pathways of inflammation. For example 
quercetin a) inhibits DC and T cell activation, maturation and migration; b) reduces the 
production of nitric oxide (NO), rheumatoid factor (RF), C-reactive protein (CRP), 
cytokines, chemokines and prostaglandins (examples include TNF-, IL-1, IL-1, 
INF, MCP-1, IL-6, IL-10, IL-12 p70, MIP-1a, MIP-1b, RANTES and PGE-2); c) 
Ac
cep
t d
 M
anu
scr
ipt
4 | P a g e
reduces the expressions of costimulatory molecules such as CD40, CD80, and CD86; 
d) prevents angiogenesis; e) inhibits transcription factors such as NF-; f) reduces 
enzymes like MMPs, COX, hyaluronidases and collagenases; g) promotes apoptosis of 
pathogenic cells, and h) inhibits oxidative metabolism [21, 25-33].
In summary, despite methotrexate being an effective drug for RA, it is not specific for 
the disease and puts at risk the life of patients. Alternative therapies are required to treat 
RA. In the present study, anti-inflammatory and joint protective properties of quercetin 
were studied using C57BL/6 collagen-induced arthritis mouse model. 
2. Materials and Methods
2.1. Reagents
Chicken Type II collagen, Complete Freund’s Adjuvant (CFA), Incomplete Freund’s 
Adjuvant (IFA), methotrexate and quercetin were purchased from Sigma-Aldrich (St 
Louis, MO, USA). Phosphate Buffer Saline (PBS) was acquired from Thermo Fisher 
(Newstead, QLD, Australia). The cytokine kits were purchased from BD Biosciences 
(North Ryde, NSW, Australia).
2.2. Induction and evaluation of collagen-induced arthritis
Mice were injected sub dermally at day 0 with an emulsion containing chicken type II 
collagen and CFA. Following the first injection, mice received a booster injection at 
day 21 with an emulsion of chicken type II collagen and IFA. Every five days, collagen-
induced arthritis was evaluated by visual scoring of the paws including the adjoining 
area. In addition, swelling in the ankles was measured with digital calipers. Each paw 
was scored from 0 to 4 as follows: 0 = normal, 1 = erythema and mild swelling, 2 = 
erythema and swelling extending to ankle joints and one or two toes, 3 = erythema and 
swelling extending to metatarsal joints and more than two toes and 4 = ankylosing 
deformity with joint swelling. Scores from the four paws were added to get a 
cumulative score of 0 to 16.
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2.3. Treatment groups
C57BL/6 mice aged 10-12 weeks were obtained from the Small Animal Breeding 
Facility of James Cook University. The James Cook University Animal Ethics 
Committee approved all studies. Mice were allocated into five groups according to the 
treatment: 1) Negative Control (Control), 2) Positive Control (Arthritis), 3) 
Arthritis+Mtx, 4) Arthritis+Que and 5) Artritis+Mtx+Que. 
The negative control group did not receive any treatment. Arthritis was induced in the 
following groups: Arthritis, Arthritis+Mtx, Arthritis+Que and Arthritis+Mtx+Que. In 
addition, each mouse from these groups received daily treatments from day 21 to day 
70. The Arthritis group received subcutaneous injections of 100 l of PBS. The 
Arthritis+Mtx group was treated intraperitoneally (i.p.) with 0.5 mg/kg of methotrexate. 
The Arthritis+Que was treated daily by oral gavage with 30 mg/kg of quercetin. The 
Arthritis+Mtx+Que group was treated with both methotrexate (0.5 mg/kg i.p) and 
quercetin (30 mg/kg oral gavage, daily).
2.4. Cytokine Assay
Mice were sacrificed by exsanguination under deep anesthesia 24 h after final treatment 
(day 71) and blood was collected by cardiac puncture. Plasma was separated from blood 
by centrifugation (1000g for 15 minutes). Plasma was stored at -80C until it was tested 
to detect pro- and anti-inflammatory cytokines. Quantitative measurement of cytokines 
was performed with a Quantibody: Multiplex array (BD Pharmigen). Samples were 
assayed following the protocol of BD Pharmigen in a CyAn ADP (Beckman Counter) 
flow cytometer. 
2.5. Radiographic Examination
From each group a mouse was chosen at random and anesthetized at the end of the 
experiment (day 70). X-ray examination was carried out with a Multi Soft X-ray film 
apparatus. 
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2.6. Histopathological Analysis
Left hind knees were dissected out, cleaned and samples were fixed, decalcified and 
embedded in paraffin to be sectioned. Sections of 5 µm were stained with Hematoxylin 
and Eosin for a blind histopathological examination. Histopathological scoring (Table 
1) was performed by a pathologist blinded to the identity of the sample group.
As histopathological scores differed among the groups, the medians of each group - 
including synovitis, pannus formation, cell infiltration and cartilage and bone damage 
- were obtained to exemplify the arthritic distribution. Further analysis of the minimum, 
maximum and total scores of synovitis including pannus formation, cell infiltration, 
cartilage damage, and bone damage was done using column analysis. The means were 
rounded to the nearest integer and represented as (–) normal, (+) minimum, (++) 
moderate, and (+++) maximum damage in the knee.
2.7. Statistical analysis
GraphPad Prism Version 7.0a was used for data analysis. Data were analysed by two-
way ANOVA with Dunnett’s multiple comparisons test; one-way ANOVA with 
Kruskal-Wallis test and Dunn’s multiple comparisons test; column statistics and Mann-
Whitney U test. Results are reported as mean ± SEM. Mean results from the 
histopathological analysis were rounded to the nearest integer and illustrated with (– ) 
and (+) symbols. P values below 0.05 were considered statistically significant. 
3. Results
3.1. Weight loss and mortality
Each mouse was weighed at 5 day intervals to determine whether methotrexate and 
quercetin had an effect on weight gain (Fig. 1A). The mouse weight was not influenced 
either by arthritis, arthritis+methotrexate or arthritis+quercetin when compared to the 
control group. However, when comparing the control group with the 
Arthritis+Mtx+Que group, the weights in the latter group had significantly decreased 
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from day 10 to day 70. Mice also lost weight at 45, 55, 60 and 65 days when the Arthritis 
group was compared with the Arthritis+Mtx+Que group. While none of the other 
groups showed mortality, the Arthritis+Mtx+Que group had 16.6% mortality (Table 2). 
Thus the combined administration of methotrexate and quercetin caused a significant 
weight loss and mortality in mice. 
3.2. Paw oedema 
All four paws were visually examined and scored for oedema to determine whether 
quercetin plays a protective role in collagen-induced arthritis (Fig. 1B and Table 2). 
The negative control group did not show signs of oedema. All mice with CIA showed 
signs of oedema in the four paws. Mice with arthritis treated with methotrexate or 
quercetin showed reduced paw oedema from day 50 to day 70 compared to mice with 
arthritis but without treatment. Mice also showed reduced paw oedema from day 60 to 
day 70 when methotrexate and quercetin were administered together. The number of 
mice with a maximum score in any paw was higher in mice with arthritis and mice with 
arthritis treated with methotrexate. The number of paws with maximum score was 
higher in mice with arthritis. The maximum score of paw oedema was seen for 10 to 35 
days in mice with arthritis, 5 days in mice with arthritis treated with methotrexate or 
quercetin and 1 day in mice with arthritis treated with methotrexate + quercetin. The 
cumulative disease decreased significantly in mice treated only with quercetin, 
particularly the severity of oedema. It is shown that the beneficial effect of methotrexate 
and quercetin in oedema was delayed when these drugs were administered 
concurrently. As stated, the administration of methotrexate + quercetin decreased the 
severity of oedema but not more than quercetin alone. 
3.3. Ankle thickness
The width of the ankles was measured every five days to determine the role of quercetin 
in ankle inflammation (Fig. 1C-D). Thickness of the left and right ankles differed 
significantly between the control group and the arthritis group from day 35 in the left 
paw and from day 40 in the right paw to day 70 in both paws. Even though the thickness 
of the left ankle seemed to be lower in mice treated with quercetin compared to those 
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with arthritis, significant differences between these groups was seen only on day 65. 
No significant differences were observed when the arthritis group was compared with 
the Arthritis+Mtx group or the Arthritis+Mtx+Que group. These results indicated that 
quercetin did not have a significant effect in reducing ankle oedema.
3.4. Radiological examination of the knee joint
A representative mouse from each group was chosen at random. A radio-graphic image 
was taken of the hind limbs at 70 days (Fig. 2), to examine the join damage during CIA. 
Joints showed narrow joint spaces, diffuse soft tissue swelling, cystic enlargement of 
bone, and erosions in arthritis mice. There was apparent degeneration of joint structure 
in the mouse with arthritis and no treatment compared to the negative control. However, 
bone erosion and degradation were not severe, and the extent of the narrowing of joint 
space was observed to be relatively small in the treatment groups (Fig. 2).
3.5. Histopathological changes in mice treated with Que and Mtx
Histopathological evaluation of knees was performed to examine the degree of arthritic 
damage (Fig. 3A-F and Table 2 and 3). The control group did not show pathological 
signs of arthritis as illustrated (Fig. 3A-B and Table 2 and 3). The distribution of the 
histopathological scores of the groups varied significantly (p = 0.0129 vs Arthritis 
group by Kruskal-Wallis). Minimal synovitis including pannus formation, 
inflammatory cell infiltration, cartilage and bone damage was seen in the Arthritis, 
Arthritis+Mtx, Arthritis+Que and Arthritis+Mtx+Que groups. Maximal synovitis with 
pannus formation and inflammatory cell infiltration was seen in the Arthritis, 
Arthritis+Mtx and Arthritis+Mtx+Que groups but not in mice treated with quercetin. 
The Arthritis+Que group showed moderate synovitis with moderate pannus formation 
and inflammatory cell infiltration. Maximal cartilage and bone damage was seen in the 
Arthritis and Arthritis+Mtx+Que groups. The Arthritis+Mtx and Arthritis+Que groups 
showed moderate damage to cartilage and bone (Fig D and E).
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The Arthritis group showed maximal synovitis including pannus formation with 
moderate inflammatory cell infiltration, cartilage and bone damage. The Arthritis+Mtx 
group showed maximal inflammatory cell infiltration with moderate synovitis, pannus 
formation, cartilage and bone damage. The Arthritis+Que group showed minimal 
synovitis, pannus formation, inflammatory cell infiltration, cartilage and bone damage. 
The Arthritis+Mtx+Que group showed moderate synovitis, pannus formation, cell 
infiltration, cartilage damage and bone destruction. Interestingly, only mice treated with 
quercetin showed minimal damage to joints (Fig 3E and Table 2 and 3) clearly 
indicating that quercetin protected the knee from synovitis, pannus formation, cartilage 
and bone damage.
3.6. Effect of treatment on cytokine levels
At the conclusion of the study, plasma was analysed to find whether changes in 
cytokine levels influenced the inflammatory changes observed in mice. There were 
mimimal circulating levels of TNF-, IL-6, IL-1, IL-17, IL-1 and MCP-1 in the 
control group when compared with the arthritis group (Figs. 4A-F). Levels of TNF 
and IL-1  (Fig. 4A and C) were significantly reduced in groups of mice treated with 
methotrexate, quercetin and methotrexate + quercetin. Plasma levels of IL-6 (Fig. 4B) 
were significantly reduced in mice treated with methotrexate+quercetin. IL-17 (Fig. 
4D) was significantly decreased in mice treated with methotrexate or quercetin. Levels 
of IL-1 (Fig. 4E) were reduced in mice treated with methotrexate. Plasma MCP-1 
(Fig. 4F) was decreased in mice treated with quercetin and methotrexate+quercetin. 
Decreases in the severity of CIA in all groups of mice was associated with lower 
circulating levels of TNF- and IL-1. The lowest indicators of arthritis in mice treated 
with quercetin were associated with significantly reduced levels of IL-17 and MCP-1.
4. Discussion
The present study is the first work in vivo examining the therapeutic role of quercetin 
in CIA in C57BL/6 mice, and comparing the beneficial effects of methotrexate and 
methotrexate combined with quercetin in experimental RA. The control group did not 
show signs of either oedema or inflammation (Fig. 1B-D, 2, 3A-B and Tables 2 and 3). 
Consistent with the absence of the disease, the control group had the lowest levels of 
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TNF-, IL-6 and IL-17 (Figs. 4A-B and AF). Although the control group had higher 
levels of IL-1, IL-1 and MCP-1 than mice treated with methotrexate, quercetin or 
methotrexate + quercetin, no statistical significant differences were seen between the 
groups (Fig. 4C and 4E-F). Our finding are in agreement with previous studies in RA 
and CIA that methotrexate reduces the severity of oedema and inflammatory damage 
in the joints (Fig. 1B-D, 2, 3D, and Tables 2 and 3) [34-37]. Although methotrexate 
decreased circulating levels of TNF-, IL-1, IL-17 and IL-1  (Fig. 4A and 4C-E), it 
did not have a superior anti-inflammatory or protective effects on the joint tissue 
compared to quercetin alone. 
The present study also found that the administration of both methotrexate + quercetin 
had no significant combined effect either on the severity of disease or joint destruction 
when compared to solo therapeutic agent. However the combination of two agents did 
result in weight loss and death. While Methotrexate has been reportedly caused weight 
loss and death in RA in a previous study [38], to our knowledge, there are no reports 
indicating that quercetin causes death in RA or in animal models of the disease. 
However, studies in vitro showed that quercetin inhibited the differentiation of pre-
adipocytes, suppressed intracellular accumulation of lipids and participated actively in 
the breakdown of lipids [39]. Death of the mice could be caused because of the toxicity 
caused by sustained treatment (day 21 to day 70) of methotrexate. Weight loss may be 
due to a joint action of toxicity, prevention of adipogenesis and acceleration of lipolysis.
Here it is shown that oral administration of quercetin in CIA in C57BL/6 mice 
decreased paw oedema but not ankle oedema following 4 weeks of treatment (Fig. 1B-
D, 2 and Table 2 and3). Reduction of paw oedema by quercetin was seen throughout 
the experiment from day 50 to day 70. Quercetin also shortened the duration of the 
maximum severity of oedema. In previous studies Rockland mice with acute 
inflammation caused by carrageenan had decreased oedema after intraperitoneal (i.p) 
administration of quercetin [40]. Wistar rats with adjuvant-carrageenan-induced 
inflammation (ACII) showed reduced acute and chronic paw oedema following i.p 
administration of quercetin [40, 41]. Wistar rats with CFA-induced arthritis had 
diminished oedema after oral administration of quercetin alone or quercetin-loaded 
quantum dots (QDs-QE complex) [26]. Decreased oedema after oral or intra-cutaneous 
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(i.c.) administration of quercetin was observed in Lewis rats with adjuvant arthritis 
(AA). The positive properties of quercetin on reducing oedema was not affected by the 
mode of delivery of the agent.  In contrast to the above findings. Choi E et al. [28] found 
quercetin had no effect in reducing swelling of DBA/1J mice with CIA. Gardini C, et 
al. [21] also reported that quercetin did not decrease oedema in Lewis rats with AA, 
however. The clinical signs of arthritis in Lewis rats were only reported for days 14 and 
28. Javadi F et al. [18] found that quercetin decreased stiffness and pain but not swelling 
in women with RA. It is known from previous findings that the effect of quercetin in 
arthritic inflammation are dose dependent [26, 31].  Choi E et al. [28] fed DBA/1J mice 
with a diet containing 0.05% of quercetin for nine weeks. Gardini C, et al. [21] 
administered 150 mg/kg/day to Lewis rats for 28 days. Javadi F et al. [18] supplemented 
women with 500 mg/day of quercetin for 8 weeks. If the beneficial effects of quercetin 
on the development of oedema are dose dependent, it is possible that the lack of effect 
of quercetin in mouse studies is possibly related to dose or mouse strain variation. 
Conflicting results in rats could be related to i.c. administration of quercetin which 
caused a relapse of the oedema for two days (days 28 and 36) in rats [31]. Although 
differences in animal models appeared not to be related to the period of administration, 
extended duration of clinical trials in humans and a reduction in the frequency of 
assessing for clinical signs could be factors to be considered in future studies. 
In our studies, the reduction of oedema was confirmed in the histopathological analysis 
of the knees. Firstly, we found that the density of inflammatory cells occupying the 
synovial compartment was minimal in mice treated with quercetin (Figs. 3E, 3G and 
Table 2). This is not unexpected as it has been previously demonstrated in one study of 
arthritic rats that white blood cell numbers decrease after QDs-QE complex treatment 
[26]. This is due to liposomes containing quercetin obstructing DNA binding in targeted 
APCs in inflammatory arthritis [42]. C57BL/6 mice immunized with OVA and IFA 
have also demonstrated that quercetin can inhibit Ag-specific T cell activation [43]  and 
inhibit DC Ag loading and blocked DC response to CCL21 in vitro. Therefore it appears 
that the low cellularity observed in the synovial compartment in our studies is due to 
the effect of quercetin on activation, maturation, proliferation and migration of 
inflammatory cells infiltrating the synovial space. Secondly, the group of mice treated 
with quercetin was the only group showing minimal hyperplasia with limited pannus 
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formation (Figs. 3E, 3G and Table 3). Earlier reports indicated that quercetin inhibited 
HIG-82 rabbit synoviocyte viability and proliferation as well as angiogenesis after 
stimulation with dimethylthiazol diphenyltetrazolium bromide salt (MTT) [17]. The 
antiangiogenic effect of quercetin was also demonstrated in vitro and in vivo 
experiments using human umbilical vein endothelial cells and chicken chorioallantoic 
membrane respectively [33]. Additionally, Tan WF et al. [33] reported that quercetin 
inhibited the proliferation of NIH-3T3 fibroblast cells, while studies in RA patients 
revealed that quercetin induced apoptosis of fibroblast-like synoviocytes (FLS) by 
activating p53, reducing cytochrome c release and inhibiting Bcl-2, Bax and IL-1 [25, 
44]. Apoptosis induced by quercetin has also been reported in DC [43]. This evidence 
suggests that quercetin prevents hyperplasia and facilitates apoptosis of cells that cause 
pathology. As synoviocytes and fibroblasts lose their ability to survive and multiply, 
the formation of fibroblast-type synovial lesions is interrupted. Pannus formation is also 
prevented as the antiangiogenic properties of quercetin block the growth of new blood 
vessels. 
Quercetin treatment of mice in this study was associated with minimal inflammatory 
cell infiltration and minimal hyperplasia due to the flavonoid reducing circulating levels 
of TNF-, IL-1, IL-17 and MCP-1 (Figs. 4A, 4C, 4D and 4F) [21, 28].  Quercetin 
treatment has also been shown to reduce plasma levels of IL1 in Lewis rats with AA 
[21] and plasma levels of TNF- of women with RA [18]. In vitro studies have reported 
that TNF- inhibits the activation of NF-k, MCP-1 and IL-8 in human synovial cells 
[45]. Decreased propagation of fibroblasts reduce the level of IL-1 and this decrease 
in   IL-1 affected the production and proliferation of MMPs, COX-2, PGE2; 
phosphorylation of ERK-1/2, p38, JNK; and activation of NF-kB [17, 44]. It seems that 
low levels of cytokines after quercetin treatment is consistent with the low cellularity 
found in the synovial compartment. Moreover, quercetin is known to affects NF-kB 
activation which decreased cytokine expression [44]. 
We found that mice treated with quercetin exhibited the highest protection to cartilage 
and bone than other groups included in the study (Figs. 3A, 3G and Table 3). Minimal 
degradation in bone and cartilage could be associated with lower circulating levels of 
IL-17, as this cytokine activates osteoclasts [46]. It has been demonstrated in in vitro 
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studies that quercetin regulates glycosaminoglycans and inhibits the expression of 
MMP3 in proteoglycans [17, 47]. QDs-QE complex also increased levels of SOD, 
CAT, GPx and GSH, which inhibited cartilage degradation by ROS [26]. Despite the 
limited information existing about the role of quercetin in cartilage and bone 
remodelling, it likely that quercetin can directly protect cartilage.  It is possible that 
minimal damage to cartilage and bone that was observed in this study was related to 
decreased levels of IL-17.  
5. Conclusions
Despite the therapeutic risks of methotrexate, it has been the most used treatment for 
RA. Therefore it is essential to continue searching for new drugs to improve patient 
outcome. This study demonstrated that quercetin could be a potential new therapy for 
RA. Quercetin diminished the severity of clinical signs of CIA and protected cartilage 
and bone from destruction. Protection against CIA was associated with decreased 
circulating levels of TNF-, IL-1, IL-17 and MCP-1. Interestingly, quercetin was 
shown to be a better anti-inflammatory, immunosuppressive and protective therapy 
than methotrexate using the CIA model. However, the beneficial properties of quercetin 
were not enhanced by methotrexate + quercetin; on the contrary it caused significant 
weight loss in animals and requires further investigation. Quercetin could have a role 
in the treatment of RA as it decreases the severity of arthritic inflammation, protects 
joints from degradation and is non-toxic at a therapeutic concentration. 
Conflict of interest
The authors declare no conflict of interest.
Acknowledgement
The authors would like to thank Arthritis Australia (The HJ & GJ McKenzie Grant 
2015) and Australian Institute of Tropical Health and Medicine, James Cook University 
for funding this project.
Ac
cep
ted
 M
anu
scr
ipt
14 | P a g e
References[1] I. Ahlstrand, M. Bjork, I. Thyberg, B. Borsbo, T. Falkmer, Pain and daily activities in rheumatoid arthritis, Disability and rehabilitation 34(15) (2012) 1245-53.[2] K. Yamamoto, Y. Okada, A. Suzuki, Y. Kochi, Genetics of rheumatoid arthritis in Asia--present and future, Nature reviews. Rheumatology 11(6) (2015) 375-9.[3] H. Midtbo, E. Gerdts, T.K. Kvien, I.C. Olsen, M.T. Lonnebakken, E.S. Davidsen, S. Rollefstad, A.G. Semb, The association of hypertension with asymptomatic cardiovascular organ damage in rheumatoid arthritis, Blood pressure 25(5) (2016) 298-304.[4] L. Tong, J. Thumboo, Y.K. Tan, T.Y. Wong, S. Albani, The eye: a window of opportunity in rheumatoid arthritis?, Nature reviews. Rheumatology 10(9) (2014) 552-60.[5] C.A. Kelly, V. Saravanan, M. Nisar, S. Arthanari, F.A. Woodhead, A.N. Price-Forbes, J. Dawson, N. Sathi, Y. Ahmad, G. Koduri, A. Young, Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics--a large multicentre UK study, Rheumatology (Oxford, England) 53(9) (2014) 1676-82.[6] E. Pathan, V.R. Joshi, Rheumatoid arthritis and the kidney, The Journal of the Association of Physicians of India 52 (2004) 488-94.[7] G. Titeca, L. Goudetsidis, A. Laka, D. Jardinet, F. Poot, [Rheumatoid neutrophilic dermatitis], Annales de dermatologie et de venereologie 141(10) (2014) 603-6.[8] S.M. Naz, D.P. Symmons, Mortality in established rheumatoid arthritis, Best practice & research. Clinical rheumatology 21(5) (2007) 871-83.[9] C. Terao, S. Raychaudhuri, P.K. Gregersen, Recent Advances in Defining the Genetic Basis of Rheumatoid Arthritis, Annual review of genomics and human genetics 17 (2016) 273-301.[10] P. Castro-Santos, R. Diaz-Pena, Genetics of rheumatoid arthritis: a new boost is needed in Latin American populations, Revista brasileira de reumatologia 56(2) (2016) 171-7.[11] D. Alpizar-Rodriguez, N. Pluchino, G. Canny, C. Gabay, A. Finckh, The role of female hormonal factors in the development of rheumatoid arthritis, Rheumatology (Oxford, England)  (2016).[12] S.F. Jalil, M. Arshad, A. Bhatti, J. Ahmad, F. Akbar, S. Ali, P. John, Rheumatoid arthritis: What have we learned about the causing factors?, Pakistan journal of pharmaceutical sciences 29(2) (2016) 629-45.[13] J.S. Smolen, D. Aletaha, I.B. McInnes, Rheumatoid arthritis, Lancet (London, England) 388(10055) (2016) 2023-2038.
Ac
cep
ted
 M
anu
scr
ipt
15 | P a g e
[14] V.C. Romao, A. Lima, M. Bernardes, H. Canhao, J.E. Fonseca, Three decades of low-dose methotrexate in rheumatoid arthritis: can we predict toxicity?, Immunologic research 60(2-3) (2014) 289-310.[15] J.M. Harnly, R.F. Doherty, G.R. Beecher, J.M. Holden, D.B. Haytowitz, S. Bhagwat, S. Gebhardt, Flavonoid content of U.S. fruits, vegetables, and nuts, Journal of agricultural and food chemistry 54(26) (2006) 9966-77.[16] R. Garcia-Mateos, L. Aguilar-Santelises, M. Soto-Hernandez, R. Nieto-Angel, Flavonoids and antioxidant activity of flowers of Mexican Crataegus spp, Natural product research 27(9) (2013) 834-6.[17] J.K. Jackson, T. Higo, W.L. Hunter, H.M. Burt, The antioxidants curcumin and quercetin inhibit inflammatory processes associated with arthritis, Inflammation research : official journal of the European Histamine Research Society ... [et al.] 55(4) (2006) 168-75.[18] F. Javadi, A. Ahmadzadeh, S. Eghtesadi, N. Aryaeian, M. Zabihiyeganeh, A. Rahimi Foroushani, S. Jazayeri, The Effect of Quercetin on Inflammatory Factors and Clinical Symptoms in Women with Rheumatoid Arthritis: A Double-Blind, Randomized Controlled Trial, Journal of the American College of Nutrition  (2016) 1-7.[19] Y.D. Min, C.H. Choi, H. Bark, H.Y. Son, H.H. Park, S. Lee, J.W. Park, E.K. Park, H.I. Shin, S.H. Kim, Quercetin inhibits expression of inflammatory cytokines through attenuation of NF-kappaB and p38 MAPK in HMC-1 human mast cell line, Inflammation research : official journal of the European Histamine Research Society ... [et al.] 56(5) (2007) 210-5.[20] V. Natarajan, N. Krithica, B. Madhan, P.K. Sehgal, Formulation and evaluation of quercetin polycaprolactone microspheres for the treatment of rheumatoid arthritis, Journal of pharmaceutical sciences 100(1) (2011) 195-205.[21] C. Gardi, K. Bauerova, B. Stringa, V. Kuncirova, L. Slovak, S. Ponist, F. Drafi, L. Bezakova, I. Tedesco, A. Acquaviva, S. Bilotto, G.L. Russo, Quercetin reduced inflammation and increased antioxidant defense in rat adjuvant arthritis, Archives of biochemistry and biophysics 583 (2015) 150-7.[22] K. Cimanga, L. Ying, T. De Bruyne, S. Apers, P. Cos, N. Hermans, P. Bakana, L. Tona, K. Kambu, D.T. Kalenda, L. Pieters, D. Vanden Berghe, A.J. Vlietinck, Radical scavenging and xanthine oxidase inhibitory activity of phenolic compounds from Bridelia ferruginea stem bark, The Journal of pharmacy and pharmacology 53(5) (2001) 757-61.[23] C. Grundemann, C.W. Gruber, A. Hertrampf, M. Zehl, B. Kopp, R. Huber, An aqueous birch leaf extract of Betula pendula inhibits the growth and cell division of inflammatory lymphocytes, Journal of ethnopharmacology 136(3) (2011) 444-51.[24] Y. Yang, T. Yu, H.J. Jang, S.E. Byeon, S.Y. Song, B.H. Lee, M.H. Rhee, T.W. Kim, J. Lee, S. Hong, J.Y. Cho, In vitro and in vivo anti-inflammatory activities of 
Ac
cep
te
 M
anu
cri
pt
16 | P a g e
Polygonum hydropiper methanol extract, Journal of ethnopharmacology 139(2) (2012) 616-25.[25] P. Xiao, Y. Hao, X. Zhu, X. Wu, p53 contributes to quercetin-induced apoptosis in human rheumatoid arthritis fibroblast-like synoviocytes, Inflammation 36(2) (2013) 272-8.[26] R. Jeyadevi, T. Sivasudha, A. Rameshkumar, D.A. Ananth, G.S. Aseervatham, K. Kumaresan, L.D. Kumar, S. Jagadeeswari, R. Renganathan, Enhancement of anti arthritic effect of quercetin using thioglycolic acid-capped cadmium telluride quantum dots as nanocarrier in adjuvant induced arthritic Wistar rats, Colloids and surfaces. B, Biointerfaces 112 (2013) 255-63.[27] J. Lattig, M. Bohl, P. Fischer, S. Tischer, C. Tietbohl, M. Menschikowski, H.O. Gutzeit, P. Metz, M.T. Pisabarro, Mechanism of inhibition of human secretory phospholipase A2 by flavonoids: rationale for lead design, Journal of computer-aided molecular design 21(8) (2007) 473-83.[28] E.J. Choi, S.C. Bae, R. Yu, J. Youn, M.K. Sung, Dietary vitamin E and quercetin modulate inflammatory responses of collagen-induced arthritis in mice, Journal of medicinal food 12(4) (2009) 770-5.[29] E.O. Santos, L.M. Kabeya, A.S. Figueiredo-Rinhel, L.F. Marchi, M.F. Andrade, F. Piatesi, A.B. Paoliello-Paschoalato, A.E. Azzolini, Y.M. Lucisano-Valim, Flavonols modulate the effector functions of healthy individuals' immune complex-stimulated neutrophils: a therapeutic perspective for rheumatoid arthritis, International immunopharmacology 21(1) (2014) 102-11.[30] J.H. Lee, G.H. Kim, Evaluation of antioxidant and inhibitory activities for different subclasses flavonoids on enzymes for rheumatoid arthritis, Journal of food science 75(7) (2010) H212-7.[31] M. Mamani-Matsuda, T. Kauss, A. Al-Kharrat, J. Rambert, F. Fawaz, D. Thiolat, D. Moynet, S. Coves, D. Malvy, M.D. Mossalayi, Therapeutic and preventive properties of quercetin in experimental arthritis correlate with decreased macrophage inflammatory mediators, Biochemical pharmacology 72(10) (2006) 1304-10.[32] C.N. Tran, S.K. Lundy, D.A. Fox, Synovial biology and T cells in rheumatoid arthritis, Pathophysiology : the official journal of the International Society for Pathophysiology 12(3) (2005) 183-9.[33] W.F. Tan, L.P. Lin, M.H. Li, Y.X. Zhang, Y.G. Tong, D. Xiao, J. Ding, Quercetin, a dietary-derived flavonoid, possesses antiangiogenic potential, European journal of pharmacology 459(2-3) (2003) 255-62.[34] M.A. Lopez-Olivo, H.R. Siddhanamatha, B. Shea, P. Tugwell, G.A. Wells, M.E. Suarez-Almazor, Methotrexate for treating rheumatoid arthritis, The Cochrane database of systematic reviews (6) (2014) Cd000957.
Ac
cep
ted
Ma
nu
scr
ipt
17 | P a g e
[35] N. Lorenzo, F. Altruda, L. Silengo, M. Del Carmen Dominguez, APL-1, an altered peptide ligand derived from heat-shock protein, alone or combined with methotrexate attenuates murine collagen-induced arthritis, Clinical and experimental medicine  (2016).[36] S.W. Lee, J.H. Kim, M.C. Park, Y.B. Park, W.J. Chae, T. Morio, D.H. Lee, S.H. Yang, S.K. Lee, S.K. Lee, S.K. Lee, Alleviation of rheumatoid arthritis by cell-transducible methotrexate upon transcutaneous delivery, Biomaterials 33(5) (2012) 1563-72.[37] Y.H. Kim, J.S. Kang, Effect of methotrexate on collagen-induced arthritis assessed by micro-computed tomography and histopathological examination in female rats, Biomolecules & therapeutics 23(2) (2015) 195-200.[38] C. Salliot, D. van der Heijde, Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research, Annals of the rheumatic diseases 68(7) (2009) 1100-4.[39] Y.S. Seo, O.H. Kang, S.B. Kim, S.H. Mun, D.H. Kang, D.W. Yang, J.G. Choi, Y.M. Lee, D.K. Kang, H.S. Lee, D.Y. Kwon, Quercetin prevents adipogenesis by regulation of transcriptional factors and lipases in OP9 cells, International journal of molecular medicine 35(6) (2015) 1779-85.[40] A.E. Rotelli, T. Guardia, A.O. Juarez, N.E. de la Rocha, L.E. Pelzer, Comparative study of flavonoids in experimental models of inflammation, Pharmacological research 48(6) (2003) 601-6.[41] T. Guardia, A.E. Rotelli, A.O. Juarez, L.E. Pelzer, Anti-inflammatory properties of plant flavonoids. Effects of rutin, quercetin and hesperidin on adjuvant arthritis in rat, Farmaco (Societa chimica italiana : 1989) 56(9) (2001) 683-7.[42] C. Capini, M. Jaturanpinyo, H.I. Chang, S. Mutalik, A. McNally, S. Street, R. Steptoe, B. O'Sullivan, N. Davies, R. Thomas, Antigen-specific suppression of inflammatory arthritis using liposomes, Journal of immunology (Baltimore, Md. : 1950) 182(6) (2009) 3556-65.[43] R.Y. Huang, Y.L. Yu, W.C. Cheng, C.N. OuYang, E. Fu, C.L. Chu, Immunosuppressive effect of quercetin on dendritic cell activation and function, Journal of immunology (Baltimore, Md. : 1950) 184(12) (2010) 6815-21.[44] M.S. Sung, E.G. Lee, H.S. Jeon, H.J. Chae, S.J. Park, Y.C. Lee, W.H. Yoo, Quercetin inhibits IL-1beta-induced proliferation and production of MMPs, COX-2, and PGE2 by rheumatoid synovial fibroblast, Inflammation 35(4) (2012) 1585-94.[45] M. Sato, T. Miyazaki, F. Kambe, K. Maeda, H. Seo, Quercetin, a bioflavonoid, inhibits the induction of interleukin 8 and monocyte chemoattractant protein-1 expression by tumor necrosis factor-alpha in cultured human synovial cells, The Journal of rheumatology 24(9) (1997) 1680-4.[46] Y. Lee, The role of interleukin-17 in bone metabolism and inflammatory skeletal diseases, BMB reports 46(10) (2013) 479-83.
Ac
cep
ted
 M
anu
scr
ipt
18 | P a g e
[47] V. Natarajan, B. Madhan, M.L. Tiku, Intra-Articular Injections of Polyphenols Protect Articular Cartilage from Inflammation-Induced Degradation: Suggesting a Potential Role in Cartilage Therapeutics, PloS one 10(6) (2015) e0127165.
Table 1. Histopathological score
Score Characteristics
0 No synovitis and no pannus formation, no cell infiltration, no damage to the 
cartilage, no damage to the bone
1 Mild synovitis with limited pannus formation, low cellular density of 
infiltrating cells, small isolated lesions in the cartilage and small isolated 
lesions in the bone
2 Moderate synovitis with moderate pannus formation, moderate cellular 
density of infiltrating cells, moderate lesions in the cartilage and moderate 
lesions in the bone
3 Severe synovitis with severe pannus formation, high cellular density of 
infiltrating cells, extensive damage to the cartilage and extensive damage to 
the bone.Ac
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Table 2. Effect of quercetin and methotrexate in CIA in C57BL/6  
Values are from day 20 when mice started to demonstrate clinical signs of disease (one day before 
start of treatment), *p  0.05 and *** p  0.0001 (Arthritis group versus Mtx-Methotrexate; 
Que-Quercetin and Mtx + Que groups). Medians of the groups varied significantly (p  
0.0001).
Treatment Group
Control Arthritis Arthritis+Mtx Arthritis+Que Arthritis+Mtx+Que
n 6 6 6 6 6
Incidence (%) 0 100 100 100 100
Mortality (%) 0 0 0 0 16.6
Maximum score 0 4 4 4 4
Mean of cumulative 
disease ± SEM 
0 ± 0.0*** 5.6 ± 0.9 3.1 ± 0.4 3.0 ± 0.5*  3.4 ± 0.5
Number of paws affected 0/0 24/24 24/24 24/24 24/24
Number of mice with 
maximum score in any 
paw
0 2 2 1 1
Number of paws with 
maximum arthritis score
0/24 3/24 2/24 2/24 2/24
Number of days with 
maximum score
0 10-35 5 5 1Ac
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Table 3. Histopathological examination
             Mean 
Group
Synovitis Cell
infiltration
Cartilage
damage
Bone
damage
Control — — — —
Arthritis +++ ++ ++ ++
Arthritis+Mtx ++ +++ ++ ++
Arthritis+Que + + + +
Arhtritis+Mtx+Que ++ ++ ++ ++
*Mean scores were rounded to the nearest interger and illustrated as: — = Normal, + 
Minimum, ++ = Moderate, +++ = Maximum.
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Figure Legends:
Fig 1. Effect of quercetin and methotrexate on body weight and paw edema 
A) Changes in weight of mice. Mice were weighed every five days from the day of arthritis 
induction (day 0) to day 70. B) Effect of quercetin and methrotexate on paw oedema. Arthritis 
was assessed by visual scoring of the paws on the scale of 0 to 4 for each paw. The sum of the 
scores resulted in the cumulative score. C) Effect of methrotrexate on ankle thickness. 
Thickness of ankles was measured with digital calipers. Each point represents the mean  SEM 
of six mice. Statistical differences are indicated #p  0.05 versus control group; *p  0.05 versus 
arthritis group (Two-way ANOVA with Dunnett’s multiple comparisons test). 
Fig 2. Representative X-rays of the effect of quercetin and methotrexate. Damage in the 
joints after 70 days of arthritis induction is indicated with white arrows.
Fig 3. Effect of quercetin and methotrexate on inflammatory changes in CIA.
A -B Control group showing the main histological structure of the knee joint. 
Histopathological (20x) changes of the C) arthritis group and groups with arthritis 
treated with D) methotrexate, E) quercetin and F) methotrexate + quercetin. Cartilage 
and bone damage is indicated with yellow arrows, pannus is indicated with white 
arrows, damage in the meniscus is indicated with blue arrows, and areas with fibrosis 
are indicated with black arrows.
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Fig 4. Effect of quercetin and methotrexate on plasma cytokine levels in collagen-
induced arthritis in C57/BL6 mice. A- TNF - ; B- IL-6; C- IL-1; D- IL-17; E- IL-
1; F- MCP-1;  Significance: * P<0.05; ** P<0.001
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